VIR
NASDAQ HealthcareVir Biotechnology, Inc. - Common Stock
Biotechnology
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
�� 市场数据
| 价格 | $10.75 |
|---|---|
| 成交量 | 2,329,898 |
| 市值 | 1.73B |
| 贝塔系数 | 1.660 |
| RSI（14日） | 82.2 超买 |
| 200日均线 | $6.53 |
| 50日均线 | $8.93 |
| 52周最高 | $10.94 |
| 52周最低 | $4.16 |
| Forward P/E | -4.78 |
| Price / Book | 1.96 |
🎯 投资策略评分
VIR 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (78/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 VIR in your text
粘贴任何文章、记录或帖子 — 工具将提取 VIR 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.